Details

Autor(en) / Beteiligte

• Gianni, Alessandro M
• Bregni, Marco
• Siena, Salvatore
• Brambilla, Cristina
• Di Nicola, Massimo
• Lombardi, Fabrizio
• Gandola, Lorenza
• Tarella, Corrado
• Pileri, Alessandro
• Ravagnani, Fernando
• Valagussa, Pinuccia
• Bonadonna, Gianni

Titel

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

Ist Teil von

• The New England journal of medicine, 1997-05, Vol.336 (18), p.1290-1298

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

1997

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• High-dose chemotherapy for non-Hodgkin's lymphomas is feasible because of improvements in patient care, especially the use of hematopoietic growth factors and stem-cell support. 1 – 4 In late 1987, we started a randomized study to compare MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) 5 with a regimen of high-dose sequential chemotherapy, followed by myeloablative therapy and hematopoietic stem-cell support, as initial treatment for high-risk, diffuse B-cell lymphomas. The high-dose regimen we used entailed the administration of several non–cross-resistant drugs, each at the maximal tolerated dose, mainly as single agents, within the shortest possible interval. The purpose of this high-dose sequential regimen is . . .